Cargando…

Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen

Staphylococcal toxic shock syndrome toxin 1 (TSST-1) binds to major histocompatibility complex class II molecules, and the toxin-class II complexes induce proliferation of T cells expressing V beta 2 sequences. To define the residues involved in TSST-1 binding, a set of transfectants expressing 21 H...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119443/
https://www.ncbi.nlm.nih.gov/pubmed/1460432
_version_ 1782141261885472768
collection PubMed
description Staphylococcal toxic shock syndrome toxin 1 (TSST-1) binds to major histocompatibility complex class II molecules, and the toxin-class II complexes induce proliferation of T cells expressing V beta 2 sequences. To define the residues involved in TSST-1 binding, a set of transfectants expressing 21 HLA-DR alpha chain mutants were analyzed for their abilities to bind and present TSST-1 and to present an antigenic peptide. Mutations at DR alpha positions 36 and 39 markedly decreased the ability of the DR7 molecule to bind and present TSST-1 but did not affect the ability to present an antigenic peptide. These data indicate that DR alpha residues 36 and 39, predicted to be located on an outer loop, are important in the formation of the TSST-1 binding site on DR molecules.
format Text
id pubmed-2119443
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21194432008-04-16 Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen J Exp Med Articles Staphylococcal toxic shock syndrome toxin 1 (TSST-1) binds to major histocompatibility complex class II molecules, and the toxin-class II complexes induce proliferation of T cells expressing V beta 2 sequences. To define the residues involved in TSST-1 binding, a set of transfectants expressing 21 HLA-DR alpha chain mutants were analyzed for their abilities to bind and present TSST-1 and to present an antigenic peptide. Mutations at DR alpha positions 36 and 39 markedly decreased the ability of the DR7 molecule to bind and present TSST-1 but did not affect the ability to present an antigenic peptide. These data indicate that DR alpha residues 36 and 39, predicted to be located on an outer loop, are important in the formation of the TSST-1 binding site on DR molecules. The Rockefeller University Press 1992-12-01 /pmc/articles/PMC2119443/ /pubmed/1460432 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
title Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
title_full Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
title_fullStr Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
title_full_unstemmed Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
title_short Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
title_sort identification of hla-dr alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119443/
https://www.ncbi.nlm.nih.gov/pubmed/1460432